263 related articles for article (PubMed ID: 35575484)
1. The management of cardiovascular disease risk in patients with rheumatoid arthritis.
Ahmed O; Krishnamurthy V; Kaba RA; Tahir H
Expert Opin Pharmacother; 2022 Jun; 23(8):947-958. PubMed ID: 35575484
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
Giollo A; Bissell LA; Buch MH
Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
[TBL] [Abstract][Full Text] [Related]
3. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues.
Barbhaiya M; Solomon DH
Curr Opin Rheumatol; 2013 May; 25(3):317-24. PubMed ID: 23466960
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China.
Li C; Wang XR; Ji HJ; Zhang XY; Li XF; Wang LZ; Wang CH; Wang YF; Yang R; Wang GC; Lu X; Zhu P; Chen LN; Jin HT; Liu JT; Liu XY; Sun L; Chen HY; Wei P; Wang JX; Cui LF; Shu R; Liu BL; Zhang ZL; Li GT; Li ZB; Yang J; Li JF; Jia B; Zhang FX; Tao JM; Han SL; Lin JY; Wei MQ; Liu XM; Ke D; Hu SX; Ye C; Yang XY; Li H; Huang CB; Gao M; Lai B; Li XF; Song LJ; Wang Y; Wang XY; Tang YD; Su Y; Mu R; Li ZG
Clin Rheumatol; 2017 May; 36(5):1023-1029. PubMed ID: 28342151
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk in rheumatoid arthritis: how to lower the risk?
van Breukelen-van der Stoep DF; Klop B; van Zeben D; Hazes JM; Castro Cabezas M
Atherosclerosis; 2013 Nov; 231(1):163-72. PubMed ID: 24125429
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs).
Mourouzis IS; Manolis AS; Pantos C
Curr Vasc Pharmacol; 2020; 18(5):455-462. PubMed ID: 31566134
[TBL] [Abstract][Full Text] [Related]
7. Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis.
Cho SK; Kim D; Won S; Lee J; Park B; Jang EJ; Bae SC; Sung YK
Semin Arthritis Rheum; 2018 Feb; 47(4):501-506. PubMed ID: 28863826
[TBL] [Abstract][Full Text] [Related]
8. Rheumatoid arthritis and risk of cardiovascular disease.
Meyer PW; Anderson R; Ker JA; Ally MT
Cardiovasc J Afr; 2018 Sep/Oct 23; 29(5):317-321. PubMed ID: 29583150
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: a real-life evidence from BioSTAR nationwide registry.
Duruöz MT; Ataman Ş; Bodur H; Çay HF; Melikoğlu MA; Akgül Ö; Çapkın E; Gürer G; Çevik R; Göğüş FN; Kamanlı A; Yurdakul FG; Yağcı İ; Rezvani A; Altan L
Rheumatol Int; 2024 Feb; 44(2):291-301. PubMed ID: 38157014
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment.
Fragoulis GE; Panayotidis I; Nikiphorou E
Curr Vasc Pharmacol; 2020; 18(5):431-446. PubMed ID: 31258091
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
Day AL; Singh JA
Drugs Aging; 2019 Jun; 36(6):493-510. PubMed ID: 30953327
[TBL] [Abstract][Full Text] [Related]
12. Association of rheumatoid arthritis with mortality in chronic kidney disease: a cohort study.
Ezeanuna MN; Prince DK; Alexander SA; Richards JS; Kerr GS; Jalal D; Bansal N; Liew JW; Singh N
Clin Rheumatol; 2022 Sep; 41(9):2669-2676. PubMed ID: 35610408
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for cardiovascular disease in rheumatoid arthritis.
Gabriel SE; Crowson CS
Curr Opin Rheumatol; 2012 Mar; 24(2):171-6. PubMed ID: 22249350
[TBL] [Abstract][Full Text] [Related]
15. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk in rheumatoid arthritis.
Nurmohamed MT
Autoimmun Rev; 2009 Jul; 8(8):663-7. PubMed ID: 19393192
[TBL] [Abstract][Full Text] [Related]
17. Prevention of cardiovascular disease in rheumatoid arthritis.
Hollan I; Dessein PH; Ronda N; Wasko MC; Svenungsson E; Agewall S; Cohen-Tervaert JW; Maki-Petaja K; Grundtvig M; Karpouzas GA; Meroni PL
Autoimmun Rev; 2015 Oct; 14(10):952-69. PubMed ID: 26117596
[TBL] [Abstract][Full Text] [Related]
18. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.
Westlake SL; Colebatch AN; Baird J; Kiely P; Quinn M; Choy E; Ostor AJ; Edwards CJ
Rheumatology (Oxford); 2010 Feb; 49(2):295-307. PubMed ID: 19946022
[TBL] [Abstract][Full Text] [Related]
19. Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis.
Luciano N; Barone E; Timilsina S; Gershwin ME; Selmi C
Clin Rev Allergy Immunol; 2023 Dec; 65(3):403-419. PubMed ID: 38157095
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Manifestations in Rheumatoid Arthritis.
Sanghavi N; Ingrassia JP; Korem S; Ash J; Pan S; Wasserman A
Cardiol Rev; 2024 Mar-Apr 01; 32(2):146-152. PubMed ID: 36729119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
